secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2025-01-17T23:59:59+00:00
Accession:  0000950170-25-006711
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta receives Nasdaq notice for audit committee non-compliance; cure period through Dec 2025
--------------------------------------------------------------------------------

- Nasdaq notice dated Jan 13, 2025 for failing audit committee requirement under Rule 5605(c)(2).
- Non-compliance triggered by resignation of board member Barry J. Simon, M.D. on Dec 18, 2024.
- Cure period runs until the earlier of next annual meeting or Dec 18, 2025.
- If annual meeting before June 16, 2025, compliance evidence due by June 16, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017025006711/0000950170-25-006711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017025006711/virx-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-006711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer